CD274 and neoplasm: Currently there are only two US Food and Drug Administration (FDA)-approved predictive biomarkers for immunotherapy in NSCLC: tumor PD-L1 expression assessed by immunohistochemistry (IHC)21 and tumor mutation burden (TMB)22–24; however, they are only modestly helpful.